GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

March 22, 2023

Study Completion Date

December 12, 2025

Conditions

Advanced Solid Tumors Harboring With G12C Mutation

Interventions

DRUG

GH35 Tablet

GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.

Trial Locations (2)

Fudan University Zhongshan Hospital, Shanghai

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Suzhou Genhouse Bio Co., Ltd.

OTHER